Compositions and methods for determining coronavirus neutralization titers
OwnerJames Mond, William Pat Leinert, SR. +1inventors
InventorsJames Mond, William Pat Leinert, SR., Andy Gibson
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to methods and kits for detecting neutralizing antibodies against a coronavirus (e.g., SARS-CoV-2) in a sample, such as a plasma sample or pooled plasma composition. The methods utilize a panel of SARS-CoV-2 neutralizing antibodies as a positive control. The kit may be a rapid detection kit that measures neutralizing antibodies using the provided methods.
Claims26
A method of detecting coronavirus neutralizing antibodies in a sample, which method comprises:
- (a) contacting a sample with a solid support comprising a coronavirus cell receptor immobilized thereto to form a mixture;
- (b) contacting the mixture with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein, whereby, if coronavirus neutralizing antibodies are present in the sample, the RBD binds to the coronavirus neutralizing antibodies and does not bind to the immobilized coronavirus cell receptor;
- (c) detecting and quantifying a signal from the reporter molecule, wherein the amount of detected signal is inversely proportional to the amount of coronavirus neutralizing antibodies present in the sample;
- and
- (d) performing steps (a)-(c) on a positive control comprising a panel of one or more coronavirus neutralizing monoclonal antibodies instead of the sample, and comparing the quantified signal of the positive control to the quantified signal of the sample to determine coronavirus neutralizing antibody capacity of the sample.
A method of detecting coronavirus neutralizing antibodies in a sample, which method comprises:
- (a) contacting a sample with a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein to form a mixture, wherein the RBD binds to coronavirus neutralizing antibodies if present in the sample;
- (b) contacting the mixture with a solid support comprising a coronavirus cell receptor immobilized thereto, whereby, if coronavirus neutralizing antibodies are present in the sample, the RBD bound to the coronavirus neutralizing antibodies does not bind to the immobilized coronavirus cell receptor;
- (c) detecting and quantifying a signal from the reporter molecule, wherein the amount of detected signal is inversely proportional to the amount of coronavirus neutralizing antibodies present in the sample;
- and
- (d) performing steps (a)-(c) on a positive control comprising a panel of one or more coronavirus neutralizing monoclonal antibodies instead of the sample, and comparing the quantified signal of the positive control to the quantified signal of the sample to determine coronavirus neutralizing antibody capacity of the sample.
3-4. (canceled)
9-10. (canceled)
(canceled)
22-23. (canceled)
26-42. (canceled)
A rapid detection kit for detecting coronavirus neutralizing antibodies, which comprises:
- (a) a solid support comprising a coronavirus cell receptor immobilized thereto;
- (b) a conjugate comprising a reporter molecule attached to a peptide comprising a receptor binding domain (RBD) of a coronavirus spike protein;
- (c) a positive control comprising panel of two or more coronavirus neutralizing antibodies;
- and
- (d) a negative control comprising at least one coronavirus non-neutralizing antibody.
45-54. (canceled)
Dependencies are inferred from the claim text.